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ABSTRACT
ANTINEOPLASTIC EFFECTS OF RHODIOLA CRENULATA TREATMENT ON
B16-F10 MELANOMA
MAY 2015
MAXINE C. DUDEK
B.S. UNIVERSITY OF MASSACHUSETTS AT AMHERST
M.S. UNIVERSITY OF MASSACHUSETTS AND AMHERST
Directed by: Dr. Sallie Smith Schneider

Melanoma remains an aggressive form of skin cancer with limited treatment options.
Novel methods to treat primary tumors and prevent metastatic disease can lead to
improved survival for those diagnosed with melanoma. Through this work, we have
evaluated the antineoplastic effects of Rhodiola crenulata (R. crenulata) root extracts on
B16-F10 melanoma both in vitro and in vivo. In this study, we observed that R. crenulata
treatment resulted in an increased cell death as well as a reduced cell growth,
proliferation and migration in vitro. Additionally, we observed that R. crenulata
decreased the expression of integrin β1 and vimentin, and increased expression of Ecadherin upon in vitro treatment. Further, we observed in a topical R. crenulata based
cream therapy, a more radial growth pattern of tumors as well as a reduced mitotic
activity and increased tumor necrosis. Markedly, we observed that mice supplemented
with R. crenulata orally in their drinking water also displayed reduced establishment of
metastatic foci in a disseminated model of melanoma. Collectively, these findings reveal
that R. crenulata exhibits striking anti-tumorigenic and anti-metastatic properties, and
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that this extract may increase survival and harbor potential novel adjuvant therapy for the
treatment of melanoma.
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CHAPTER I
INTRODUCTION

1.1.

Melanoma: A Brief Background

Each year, more than 76,000 people in the United States are diagnosed with melanoma,
the most aggressive form of skin cancer [1]. Associated with UV exposure, melanoma
arises from the malignant transformation of melanocytes. Melanocytes specialize in
melanogenesis or the production of melanin, a pigment that protects the skin by
absorbing and scattering harmful solar radiation [2-3]. Encapsulated in melanosomes,
melanin is transferred by microtubules to the matrix of the cytoplasm in cells located in
the outermost layer of the epidermis called keratinocytes, through calcium-dependent
adhesion type-1 transmembrane protein (cadherin) interactions [4]. Once released in the
keratinocyte’s matrix, melanin accumulates in the supernuclear region of the cytoplasm
where it acts as a barrier against environmental damages, such as pathogens, heat, UV
radiation and water loss [5].

There are five distinct stages of melanoma development that include: the common
acquired nevus (benign nevus), dysplastic nevus, radial growth phase (RGP) primary
melanoma, vertical growth phase (VGP) primary melanoma, and disseminated disease [56]. Both the benign nevus, and the dysplastic nevus arise from a malfunction in the
melanin unit that leads to an increased keratinocyte to melanocyte ratio. If left untreated,
both the benign nevus and the dysplastic nevus may begin to grow in situ. As melanoma
undergoes more vertical growth, cancerous cells are more likely to invade the lower
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dermis and penetrate through the deeper subcutaneous tissue and basement membrane,
thus resulting in an increased risk of metastatic spread [5;7]. Unfortunately, the five-year
survival rate for patients diagnosed with metastatic melanoma is less than 16.1%. [1].

1.2. Epithelial-mesenchymal transition transforms melanocytes into highly migratory and
invasive melanoma cells
One process responsible for transforming melanocytes into malignant cells is unregulated
epithelial-mesenchymal transition (EMT). During embryonic development, EMT allows
cells to migrate to their designated locations by reorganizing the cytoskeleton and altering
cells’ affinity for the extracellular matrix (ECM) [8]. In normal melanocytes, SNAIL2
and ZEB2 transcription factors active MITF-dependent melanocyte differentiation
programs. Differentiated melanocytes utilize tyrosinase to convert tyrosine into dopa and
subsequently to dopaquinone, the melanin precursor. Unregulated EMT triggers the
activation of different transcription factors like TWIST1 and ZEB1 [9]. These factors
along with others work together to disrupt MITF-dependent differentiation and
subsequent melanin production. Ultimately this instigates the conversion of melanocytes
into cancerous cells [10].

Not only is EMT responsible for the neoplastic transformation of melanocytes, but it is
also responsible for increasing a malignant cell’s ability to migrate and metastasize [1112]. As melanocytes morph into melanoma cells, E-cadherin expression is lost and
vimentin becomes heavily over-expressed by mesenchymal cells [13]. E-cadherin plays a
critical role in maintaining the structural integrity of the skin as well as melanocyte-
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keratinocyte interaction [14] while vimentin, a mesenchymal filament protein, is involved
in wound healing, angiogenesis and cancer growth [15-16]. Studies reveal that primary
melanomas over-expressing vimentin and under-expressing E-cadherin tend to have a
more metastatic incidence [13;17]. Therapy targeting vimentin over-expression and Ecadherin re-expression results in the significant reduction of tumor growth and
invasiveness in vivo [18-20]. Thus, vimentin and E-cadherin serve as useful biomarkers
for classifying melanoma subtypes [21].

1.3. The Role of Integrins and id genes in Mediating Melanoma Growth Patterns and
tumorigenesis
The progression of melanoma from a RGP to VGP is a critical step in disease
development and outcome for those with this malady. Melanoma lesions that display
radial growth patterns are typically less aggressive and more chemo-sensitive than those
displaying more vertical growth patterns. A number of items contribute to melanoma’s
ability to progress from RGP to VGP. One key factor are integrins, a family of
transmembrane glycoprotein receptors involved in determining cell shape and migration.
As melanoma transitions from RGP to VGP certain integrins like α5β1 are upregulated
[22-23]. This upregulation is responsible for altering a cancer cell’s affinity to the
extracellular matrix, promoting proteolytic enzymes that degrade the basement
membrane, and promoting several pro-survival mechanisms to prevent apoptosis [24].

Like integrins, inhibitor of DNA binding (Id) proteins are responsible for coordinating
biological processes like migration and invasion as well other cellular functions such as
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cell-fate determination, proliferation, cell cycle regulation and angiogenesis [25]. In
cancer cells, over-expression of ID genes contributes to an increased tumorigenesis,
invasiveness, and migratory behavior [26-27]. Cancer studies have reveled that therapies
targeting ID genes have potential in reducing metastatic spread [28].

1.4. Significance
At present, early detection of melanoma is the most important means to improve disease
survival. Depending on the stage at presentation, a multi-disciplinary approach to therapy
is required and treatment options often include a combination of surgical resection,
radiation, chemotherapy, and immunotherapy. Despite aggressive therapies, treatment
options remain limited and outcomes of patients with this disease, especially those with
disseminated disease, remain poor. A study reviewing the data of patients with Stage I
and Stage II melanoma revealed that patients with a previous history of cutaneous
melanoma have a 25-fold increased incidence of developing a second melanoma [29].
Given this, investigations into novel treatment options are necessary for patients with this
aggressive disease.

1.5. Rhodiola crenulata
One promising option for the treatment of melanoma is the extract derived from Rhodiola
crenulata (R. crenulata) roots. R. crenulata is a small perennial plant cultivated in barren
soils and high altitudes in the tundra regions of Siberia and the highlands of Tibet.
Traditionally, it has been prized by the people in regions where it grew for its energyenhancing ability. During the 20th century, scientists began to investigate its adaptogenic
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properties and discovered its ability to exert antioxidant effects, support DNA repair,
alleviate altitude and menopausal symptoms, and improve abilities such as physical
exercise, memory, sexual function, learning, and work capacity [30]. Additional
investigations revealed that Rhodiola increases cellular energy production, improves
oxygen utilization and alleviates depression, fatigue and anxiety through increasing the
production of serotonin, norepinephrine and dopamine [30-33]. Recent studies have
demonstrated the therapeutic potential of R. crenulata in a variety of cancers including
bladder cancer, breast cancer and glioblastoma [34-37]. Rhodiola contains many active
ingredients such as salidroside, catechol, ferulic acid, salicylic acid, quercetin, 4hydroxybenzoic acid, caffeic acid, gallic acid and 3,4-dihydroxybenzoic acid [38].
Unfortunately, determining the active ingredient responsible for Rhodiola’s activity
remains challenging, as many active components are believed to work in concert in
exerting R. crenulata’s many effects. Today, one may supplement their diet with
Rhodiola by purchasing it in powdered, encapsulated or loose-tea form. Recommended
doses range from individual to individual; however, it is suggested that one begin with
100mg Rhodiola ½ hour before breakfast on an empty stomach. If this dose is tolerated,
an additional 100mg may be taken ½ hour before lunch. Most people do not need to
exceed more than 400mg per day [30].

1.6. Rationale and Objectives
Given the anti-tumorigenic properties observed with the use of Rhodiola plant extracts,
both in vitro and in vivo, this study aimed to evaluate the therapeutic potential of R.
crenulata’s hydroalcoholic extract on melanoma. In this study, we set out to evaluate R.
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crenulata’s effects on proliferation, migration transcription and expression of key
transcripts and proteins involved in tumor progression. Further, we wanted to evaluate R.
crenulata’s effects on melanoma tumor growth and metastatic establishment in vivo.
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CHAPTER II
MATERIALS AND METHODS

2.1. R. crenulata Preparation
R. crenulata root extract was obtained in powder form from Barrington Chemical
Corporation (Harrison, NY). For cell culture experiments and oral R. crenulata
administration, R. crenulata powder was dissolved in a 10% ethanol solution in distilled
water and was filter sterilized. Cream-based R. crenulata for topical use was prepared by
the addition of 5% or 10% R. crenulata by weight to a 10% DMSO-Eucerine™ based
cream.

2.2. Cell Culture
B16-F10 murine melanoma cell culture line was utilized for this research (ATCC). Cells
were cultivated at 37°C under 5% CO2 and maintained in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% fetal bovine serum, 100 U/mL Penicillin and 100µg/mL
Streptomycin (Gibco®, Grand Island, NY).

2.3. Evaluation of Viability and Proliferation
A CellTiter96® Aqueous One Solution MTS tetrazolium compound [3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS(a)] containing an electron coupling reagent (phenazine ethosulfate; PES)
(Promega, Madison, WI) assay was performed according to the manufacturer’s
instructions in order to test for cell growth and proliferation. A total of 5 x 103 B16-F10

7

cells were seeded per well on a 96-well microtiter plate and treated with 200µg/mL R.
crenulata or ethanol vehicle control in quintuplicate. After incubation for 24, 48, and 72
hours the plate was spun at 2,000g for 1 min and treated media was decanted and
replaced with 100µl 1X PBS and 20µl of MTS reagent per well. The plate was then
incubated at 37°C in a humidified, 5% CO2 atmosphere for 3 hours. The absorbance of
each well was recorded at 490nm using an Enspire® multimode automated plate reader
(PerkinElmer, Waltham, MA). The experiment was performed in sextuplicate.

2.4. Florescent Viability/Cytotoxicity Assay
A Live/Dead assay was performed according to the manufacturer’s instructions to
evaluate the cytotoxic effects of R. crenulata. A total of 7.5 X 103 B16-F10 cells were
seeded on each well of a Lab-Tek® Chamber Slide and treated with vehicle control or
200µg/mL R. crenulata. The chamber slide was cultivated at 37°C in a humidified, 5%
CO2 atmosphere. Following 72 hours of treatment, media was decanted and replaced with
250µl 1X PBS containing 2µM Calcein and 4µM Ethidium homodimer-1. After a 3 hour
incubation period, images were captured at 20X magnification with a Nikon Eclipse
TE2000-U inverted microscope using MetaVue™ software (Universal Imaging
Corporation, Downington, PA).

2.5. Clonogenecity Assay
A total of 200 B16-F10 cells were seeded onto 60 mm tissue culture plates. After
allowing the cells to adhere for 24 hours, plates were treated with 100µg/mL R. crenulata
or vehicle control for one hour followed by exposure to 5Gy radiation or sham treatment.
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The media was replaced with the appropriate treatment every 4 days. By day 11, colonies
were observed. Plates were then washed with 1X PBS, fixed in methanol and stained with
2% crystal violet in a 50% methanol solution for 4 minutes. Colonies were defined as a
cluster of five or more cells. The number of colonies was than quantified and compared
between treatment groups. The experiment was performed in triplicate.

2.6. RNA Isolation and Real-Time PCR
B16-F10 cells were treated with 200µg/mL R. crenulata or vehicle. After 24 hours, total
RNA was extracted from cells using an acid-phenol extraction procedure [39] according
to the manufacturer’s instructions (Trizol, Invitrogen, Carlsbad, CA). Relative levels of
mRNA were determined by quantitative real-time Polymerase Chain Reaction (PCR)
using the Strategene Mx3005P real time PCR system (Agilent Technologies, La Jolla,
CA). All values were normalized to the amplification of GAPDH. The assays were
performed using the 1-step 2X Brilliant SYBR Green QRT-PCR Master Mix Kit (Agilent
Technologies) containing 200nM forward primer, 200nM reverse primer, and 100ng total
mRNA. The conditions for target mRNA amplification were performed as follows: 1
cycle of 50oC for 30 min; 1 cycle for 95oC for 10 min; 35 cycles each 95oC for 30x, 55oC
for 1 min and 72oC for 30s.

2.7. Migration assays
Migration and growth was first evaluated using a scratch wound assay. B16-F10 cells
were plated on 30mm dishes and allowed to reach 100% confluency. The tip of a 10µL
pipette was used to produce a scratch wound down the center of each plate. Immediately

9

following scratch-wound formation, control plates were treated with 100µg/mL R.
crenulata or ethanol vehicle control and cell growth was monitored over 48 hours.
Images of the plates were captured daily with Nikon Eclipse TE2000-U using
MetaviewTM software (Universal Imaging Corporation).

Additional migration analysis was performed utilizing transwell migration chambers.
B16-F10 cells were pre-treated with 100µg/mL R. crenulata or vehicle control. After 24
hours, 1x105 pre-treated cells were seeded onto a BD BioCoat™ Matrigel migration
chamber (8µm pore) plate (BD Biosciences, San Jose, CA) and treated with serum-free
DMEM. Matrigel migration chambers were placed in a 24-well plate so that they hovered
above complete DMEM in order to create a gradient for cell migration. After 24 hours of
incubation, migration chamber membranes were then fixed for 10 min with 10%
formalin, stained with 2% crystal violet for 20 min, and rinsed three times with distilled
water. Non-migrating cells were removed from the non-migrating surface of the
membrane with a cotton-tipped swab moistened with 1X PBS. The membrane was then
mounted on a microscope slide with Cytoseal™ XYL mounting medium (Richard-Allan
Scientific™). Images were captured with an Olympus BX41 light microscope using
SPOTSOFTWARE (Diagnostic Instruments, Inc., Sterling Heights, MI). The total
number of migrating cells was quantified in four representative images per membrane
sample at 20X power. The experiment was performed in triplicate.
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2.8. Cellular Adhesion Assay
Cells (1x105 B16-F10 cells) were plated on fibronectin-coated plates and treated with
200µg/mL R. crenulata or vehicle control. Following 24 hr incubation at 37oC the plate
was agitated and washed with 100µl washing buffer. Adhered cells were fixed with 50 µl
4% paraformaldehyde for 10 min, washed twice and stained with 50µl 2% crystal violet.
The plate was rinsed with H2O and allowed to dry completely overnight. The crystal
violet was solubilized in 2% SDS and the absorbance of each well was recorded at
550nm using an Enspire® multimode automated plate reader (PerkinElmer, Waltham,
MA). The experiment was performed in sextuplicate.

2.9. Melanogenesis Assay
100 or 1000 cells were seeded on a 96-well plate and treated with 50µg/mL, 100µg/mL,
200µg/mL R. crenulata or vehicle. After 96 hours, a normalized number of cells in each
group was measured for absorbance at 405nm using an Enspire® multimode automated
plate reader (PerkinElmer, Waltham, MA).

Melanogenesis was further analyzed by treating B16-F10 cells with 200µg/mL R.
crenulata or vehicle. After 24 hours, a normalized number of cells were lysed for 1 hour
at 60º C with 1N NaOH. After that, samples were measured for absorbance at 405nm
using an Enspire® multimode automated plate reader (PerkinElmer, Waltham, MA).
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2.10. Western Analysis
B16-F10 cells were treated with 200µg/mL R. crenulata or vehicle control. Following
treatment for 72 hours, cells were lysed in RIPA buffer containing phosphatase and
protease inhibitors. Lysates were collected and protein concentration was quantified
using a BCA™ Protein Assay kit (Pierce, Rockford, IL). For each sample, 40µg/mL of
protein was run at 180V for one hour on a 10% SDS PAGE polyacrylamide gel
electrophoresis and transferred onto a Whatman® Schleicher & Schuell® Westran S
PVDF protein sequencing membrane for 90 minutes at 100V at 4°C (Sigma Aldrich®, St.
Louis, MO). The membrane was blocked at room temperature for one hour using a 5%
milk TBS-T solution and was incubated at 4°C in primary antibody [rabbit anti-Vimentin
#3932 (Cell Signaling)] diluted 1:1000 in 5% BSA TBS-T solution overnight. Following
this, the membrane was incubated with secondary antibody [anti-rabbit IgG HRP-linked
Antibody #7074 (Cell Signaling, Danvers, MA)] (1:2000 in 5% milk TBS-T) for two
hours. Labeled protein bands were detected using HyGLO™ Quick Spray
chemiluminescent detection reagent (Denville Scientific Inc., South Plainfield, NJ). This
protocol was repeated for β-Actin as a normalizer for Vimentin [(Primary: mouse anti-βActin #47778 (Santa Cruz Biotechnology, Dallas, TX); Secondary: goat anti-mouse IgMGRP #2064 (Santa Cruz Biotechnology)]; β1 [(Primary: rabbit anti-β1 #4706 (Cell
Signaling, Danvers, MA); Secondary: anti-rabbit IgG HRP-linked Antibody #7074 (Cell
Signaling, Danvers, MA)] and β-Actin as a normalizer for β1 [(Primary: rabbit anti-βActin #ab8227 (abcam, Cambridge, MA)].
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2.11. Fluorescent Immunocytochemistry
1x105 B16F10 cells were plated onto glass coverslips and coated with Attachment Factor
1X (Gibco®) following the manufacturer’s protocol in a 24 well plate. Cells were treated
with 200µg/mL R. crenulata or vehicle for 72h. Next, the media was decanted and cells
were fixed with 4% paraformaldehyde at 4oC. Cells were permeablized with 0.5%
TritonX-100 and washed 3 times with 1X PBS:Glycine (130mM NaCl, 7mM Na2HPO4,
3.5mM NaH2PO4, 100mM Glycine). Cells were blocked with 1X IF Buffer (130mM
NaCl, 7mM Na2HPO4, 3.5mM NaH2PO4, 7mM NaN3, 0.1% BSA, 0.2% TritonX-100,
0.05% Tween-20) plus 10% goat serum for 1-2h. The cells were blocked with secondary
blocking buffer consisting of 1X IF buffer, 10% goat serum, and 20µg/mL goat antimouse F(ab’)2 for 30-45 min. Mouse anti-E-cadherin (BD Transduction Laboratories™,
Franklin Lakes, NJ) was diluted 1:50 in secondary blocking buffer O/N. Secondary
antibody Alexa Flour-568 goat anti-mouse (Molecular Probes, Invitrogen) was diluted
1:500 in 10% goat serum IF buffer and incubated for 45-60min. coverslips were removed
from the wells and mounted onto microscope slides with Vecta-shield Mounding
Medium for Fluorescence with DAPI (Vector Laboratories Inc., Burlingame, CA).
Images were captures with a Zeiss 200M inverted microscope at the same exposure and
time using Axiovision software 4.8.2.

2.12. Animal Studies (topical treatment of subcutaneous tumor growth)
All mouse work was completed in accordance with the National Institute of Health Guide
for the Care and Use of Laboratory Animals. Thirty eight-week-old virgin c57bl/6 female
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mice were housed individually in plastic cages and were permitted free access to food
and water. A total of 1 x 106 B16-F10 cells were implanted subcutaneously above the
scapular fat pad. Twenty-four hours following tumor implantation, daily topical R.
crenulata treatment was initiated. Treatment groups included: 10 mice treated with 5% R.
crenulata cream, 10 mice treated with 10% R. crenulata cream, and 10 mice treated with
DMSO control cream. Mice were evaluated daily and tumor volume measurements were
obtained once tumors became palpable. Tumor volume was calculated by (tumor length2
X tumor width)/2, in which the tumor length was the smaller of the two measured values.
Mice were euthanized if they appeared unhealthy, exhibited greater than 15% weight
loss, or when tumor volume exceeded 1.5 cm3. Upon euthanasia, necropsy was performed
and tissues were preserved in 10% formalin or flash frozen.

Excised tumors were paraffin embedded and stained with hematoxylin and eosin (H+E).
Images were captured with an Olympus BX41 light microscope using SPOTSOFTWARE
(Diagnostic Instruments, Inc., Sterling Heights, MI). The total number of mitotic cells
was quantified in three representative images at 40X power per tumor sample obtained
from each mouse in the DMSO and 10% R. crenulata treated groups.

2.13. Animal Studies (enteral treatment of subcutaneous tumor growth)
Twenty eight-week-old virgin c57bl/6 female mice were housed in plastic cages. Mice
were pre-treated for one day with R. crenulata (100mg/kg in their water) or vehicle
supplemented water. A total of 1 x 106 B16-F10 cells were implanted subcutaneously
above the scapular fat pad. Mice were evaluated daily and water was replaced with
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appropriate treatment every 48 hours. Tumor volume measurements were obtained once
tumors became palpable. Tumor volume was calculated by (tumor length2 X tumor
width)/2, in which the tumor length was the smaller of the two measured values. Mice
were euthanized if they appeared unhealthy or exhibited more than 15% weight loss.
Upon euthanasia, necropsy was performed and tissues were preserved in 10% formalin or
flash frozen.

2.14. Animal studies (Dissemination Model)
Sixteen eight-week-old virgin c57bl/6 female mice were housed in plastic cages. Mice
were pre-treated for three days with R. crenulata (100mg/kg in their water) or vehicle
supplemented water. A total of 1x105 B16-F10 cells were injected via lateral tail vein to
model a disseminated disease state. Mice were evaluated daily and water was replaced
with appropriate treatment every 48 hours. Mice were euthanized if they appeared
unhealthy or exhibited more than 15% weight loss. All surviving mice were euthanized
30 days following tumor injection. At the time of euthanasia, lungs were preserved in
fekete’s solution, while remaining organs were preserved in 10% formalin. Lungs were
evaluated for gross establishment of metastatic foci and photos were obtained. Formalin
fixed paraffin embedded lungs, were further analyzed histologically via H+E staining.
Representative images of H+E stained lung sections were taken using an Olympus BX41
light microscope using SPOTSOFTWARE (Diagnostic Instruments, Inc., Sterling
Heights, MI).
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2.15. Statistical Analysis
All results were analyzed using either a two-tailed student’s t-test, one-way analysis of
variance (ANOVA), or a two-ANOVA with a Bonferroni’s correction. Statistical outliers
were identified utilizing a rout test. All statistical analysis was performed with GraphPad
Prism Software (Prism, GraphPad Software, Inc., San Diego, CA).
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CHAPTER III
IN VITRO RESULTS

3.1. R. crenulata induces morphological changes and decreases proliferation and survival
in B16-F10 cells
B16-F10 cells are a well-studied mouse cell line used to model melanoma. These cells
are typically adherent, flat, and have multiple dendritic projections. We treated these cells
with increasing doses of R. crenulata and observed significant effects at 200µg/mL (Fig.
1B). Phenotypically, the B16-F10 cells treated with R. crenulata exhibited reduced
dendritic projections, became rounder and appeared less adherent (Fig. 1B). To assess R.
crenulata’s effect on growth and proliferation, we performed an MTS assay using
200µg/mL R. crenulata over time. At 24 hours, a trend towards decreased proliferation
was noted in groups treated with 200µg/mL R. crenulata (Fig. 1A) compared to vehicle
control. However, by 48 hours and 72 hrs the decrease in proliferation was significant
[(p<.01) and (p<.0001) respectively]. To evaluate the cytotoxic effects of R. crenulata on
B16-F10 cells, a live dead assay was performed. An increase in the number of dead cells
was observed in samples treated with R. crenulata (Fig. 1B), especially evident upon
administration of 200µg/mL R. crenulata.

In other cell types, we have found that treatment with R. crenulata sensitizes cancer cells
to radiation treatments [37]. Thus, we were interested in whether treatment with R.
crenulata could enhance the sensitivity of B16-F10 cells to radiation induced cell death.
To evaluate treatment efficacy via colony formation and survival, a clonogenecity assay
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was performed. In agreement with the MTS and the live dead assay, R. crenulata
significantly reduced the number (p<.001 and p<.0001 respectively) compared to vehicle
control (Fig. 1C-D). However, radiation sensitivity did not appear to be affected by the
presence of R. crenulata in this cell line.

3.2. R. crenulata increases melanogenesis in B16-F10 Melanoma Cells
As melanoma develops, the production of melanin by melanocytes may depreciate. In
order to evaluate R. crenulata’s effects on melanogenesis, we treated B16-F10 cells with
50µg/mL, 100µg/mL or 200µg/mL R. crenulata. After 96 hours, we observed a dosedependent increase in melanin content (p<.05, Fig. 2). This trend was also observed in
treated B16-F10 cells that were lysed open prior to being analyzed (data not shown).

3.3. R. crenulata inhibits migration of B16-F10 melanoma cells
As noted above, the metastatic ability of B16-F10 cells is of paramount importance to the
survival of melanoma patients. To test whether R. crenulata could affect migration of
B16-F10 cells, a scratch wound assay was performed. Plates treated with vehicle control
exhibited complete wound closure by 48 hours while plates treated with 100µg/mL R.
crenulata maintained distinct wound boundaries with minimal growth at 48 hours (Fig.
3A). We confirmed these results using a transwell migration assay. We observed a
significant reduction in the number of migrating cells in wells treated with 100µg/mL R.
crenulata for 24 hours compared to vehicle treated wells (p<.0001, Fig. 3B-C).
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3.4. R. crenulata decreases expression of ID genes, Integrin β1 and Vimentin in B16-F10
Cells
A decrease in migration could be caused by a number of different mechanisms. We had
noted in our early experiments a slight rounding and lifting of the B16-F10 cells in
response to R. crenulata treatment. To evaluate R. crenulata’s effects on cellular
adhesion, we tested the ability of R. crenulata or vehicle treated cells to adhere to a
fibronectin-coated plate. A significant decrease in adhesion was noted following 24 hours
of 200µg/mL R. crenulata treatment (p<.0001, Fig 4A). Because fibronectin interacts
with certain integrins, and integrins have been shown to be important for migration, we
examined integrins β1 protein levels by Western Analysis. Upon 72 hours of 200µg/mL
R. crenulata treatment, expression of β1 was observed to be significantly reduced
(p=.0362, Fig. 4B).

Similar to integrins, ID genes play an important role in migration and invasion. We
evaluated ID gene expression levels by qRT-PCR. Following 24 hours of 200µg/mL R.
crenulata treatment we observed an overall decrease in the expression levels of IDs 1-4
with a significant reduction in the expression levels of both ID-2 and ID-3 (p<.05, Fig.
4C).

A second pathway that is critical for migration and invasion of tumors involves epithelial
to mesenchymal transition. In this pathway the epithelial cell E-cadherin, important for
maintaining adherence junctions and melanocyte-keratinocyte interactions, is down-
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regulated while vimentin, an intermediate filament expressed in mesenchymal cells, is
upregulated. Western Analysis demonstrated that following 72 hours of 200µg/mL R.
crenulata treatment, a significant reduction in the expression levels of vimentin in B16F10 was observed (p=.0287, Fig. 4D). Immunocytochemical analyses confirm an increase
in E-cadherin levels consistent with a mesenchymal to epithelial (MET) transition
following 72 hours of treatment with 200µg/mL R. crenulata, but not observed with
vehicle control (Fig. 5).
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Figure 1. R. crenulata causes morphological changes, inhibits proliferation and decreases viability and
survival in B16-F10 cells. (A) 5,000 B16-F10 cells were seeded on a 96-well plate and treated with
200µg/mL R. crenulata or vehicle. Cell proliferation was assessed with an MTS assay at 24, 48, and 72
hours. The experiment was performed in sextuplicate. Data was compared using a one-way ANOVA with
corresponding Bonferroni t-test; bars ±SEM. Statistical significance was noted after R. crenulata treatment.
(B) Phase contrast image representation of B16-F10 cells treated with 200µg/mL R. crenulata or vehicle
(left panel). Image representation of a Viablility/Cytotoxicity Assay (right panel): 7,500 cells were seeded
on Chamber Slides and treated with 200µg/ml R. crenulata or vehicle. After 72 hours, viable and dead cells
were labeled using Calcein and Ethidium homodimer-1 respectively. Images were captured at 20X
magnification. (C) Continuous Treatment Clonogenecity Assay. 200 B16F10 cells were plated on 60mm
plates and treated as described in Material and Methods. After 8 days, surviving colonies were stained with
crystal violet and quantified. The experiment was performed in triplicate. Results were analyzed using a
two-way ANOVA with a corresponding Bonferroni t-test; bars ±SEM. Statistical significance was observed
after treatment with R. crenulata and after treatment with both R. crenulata and 5Gy irradiation. (D) Image
representation of continuous clonogenecity assay. The purple dots represent surviving crystal violet stained
colonies. (*p<.05, **p<0.01, ***p<0.001, ****p<0.0001).
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Figure 2. R. crenulata treatment increases melanogenesis in B16-F10 cells. 100 or 1000 cells were seeded
on a 96-well plate and treated with 50µg/mL, 100µg/mL, 200µg/mL R. crenulata or vehicle. 96 hours later,
a normalized number of cells were measured for absorbance at 405nm. The experiment was performed in
triplicate. Data was compared using a two-way ANOVA with corresponding Bonferroni t-test; bars ±SEM.
Statistical significance was noted after R. crenulata treatment. (*p<.05).
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Figure 3. R. crenulata decreases cell migration of B16-F10 cells. (A) Scratch Wound Healing Assay. Cells
were seeded on 60mm plates and allowed to reach confluency. Using a 10µl pipette, a scratch was made in
the middle of each plate. Cells were subsequently treated with 100µg/mL R. crenulata or vehicle. Images
were captured at 15 minutes, 4 hours, 24 hours and 48 hours at 20X magnification. (B) Migration Assay.
B16-F10 cells were treated with 100µg/mL R. crenulata or vehicle. After 24 hours, 100,000 B16-F10 cells
were plated on BD BioCoat™ Matrigel migration chambers with 8µm pores. 24 hours later, migrating cells
were stained with crystal violet and images were captures at 20X magnification. (C) The number of
migrating cells within each representative 20X field was counted. The experiment was performed in
triplicate. Data was compared using a student’s t-test; bars represent ±SEM. Statistical significance was
noted after R. crenulata treatment. (****p<.0001).
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Figure 4. R. crenulata decreases the expression of genes associated with proliferation, migration and
tumorigenesis and increases the expression of genes involved in differentiation. (A) R. crenulata decreases
the ability of B16-F10 cells to adhere to a fibronectin-coated plate. 1x105 B16-F10 cells were plated on a
fibronectin-coated plate and treated for 24 hours with 200µg/mL R. crenulata or vehicle. Adhered cells
were fixed and stained with crystal violet. The absorbance of each well was recorded at 550nm. The
experiment was performed in sextuplicate. Data was compared using a student’s t-test; bars represent
±SEM. Statistical significance was noted after R. crenulata treatment. (****p<.0001). (B) R. crenulata
treatment reduces the expression of β1 in B16-F10 cells. B16-F10 cells were treated with 200µg/mL R.
crenulata or vehicle. After 72 hours, proteins were collected, quantified, and β1 expression levels were
measured via Western Analysis. The experiment was performed in quadruplicate. Results were normalized
to β-Actin. Blots are shown above with the corresponding graph below. Bars represent ±SEM of the
relative intensity. Results significantly differed from vehicle treated cells via a student’s t-test. (*p<.05).
(C) R. crenulata reduces gene expression of genes associated with migration, invasion, and tumorigenesis.
Real-time PCR analysis was carried our for ID-1, ID-2, ID-3, and ID-4. B16-F10 cells were treated with
200µg/mL R. crenulata or vehicle. After 24 hours, total RNA was isolated. The results shown represent
experiments performed in triplicate for R. crenulata and duplicate for vehicle. All results were normalized
to GAPDH. Bars represent ±SEM of the fold change with respect to vehicle treated cells. Data was
compared using a two-way ANOVA with a corresponding Bonferroni t-test. A significant decrease was
observed in R. crenulata treated groups for ID-2 and ID-3. (*p<.05). (D) R. crenulata treatment reduces the
expression of Vimentin in B16-F10 cells. B16-F10 cells were treated with 200µg/mL R. crenulata or
vehicle. After 72 hours, proteins were collected, quantified, and Vimentin expression levels were measured
via Western Analysis. The experiment was performed in quadruplicate. Results were normalized to βActin. Blots are shown above with corresponding graph below. Bars represent ±SEM of the relative
intensity. Results significantly differed from vehicle control treated cells via a student’s t-test. (*p<.05).
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Figure 5. R. crenulata treatment increases E-cadherin expression in B16-F10 cells. B16-F10 cells were
treated with 200µg/mL R. crenulata or vehicle. After 72 hours, they were immunostained with E-cadherin
and counterstained with DAPI. Images were captured at 20X magnification; scale bar 50µm.
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CHAPTER IV
IN VIVO RESULTS

4.1. Topical R. crenulata treatment alters patterns of tumor growth in vivo
Our in vitro results suggest that R crenulata may have a potent effect on the growth and
establishment of metastasis of B16-F10 in vivo. To evaluate the effects of R. crenulata
application on B16-F10 tumors, we performed an in vivo experiment utilizing a
subcutaneous syngenic melanoma tumor model in c57bl/6 mice, which we topically
treated with R. crenulata, or vehicle in a EucerinTM based cream (Fig. 6A). Tumors were
measured daily using calipers, and for ease of measurement the pigmented region was
what was measured. Interestingly, we did observe gross differences in patterns of tumor
growth between treatment groups, although there was no difference in the overall size of
the tumor observed. The tumors in mice treated with vehicle control tended to be raised
while the tumors in the R. crenulata treated animals exhibited more outward growth over
time (Fig. 6C). Since the widths were the measured areas, no significant difference in
overall tumor size or survival was observed between the R. crenulata and vehicle control
groups. The mice treated with R. crenulata survived slightly longer: 5% R. crenulata and
10% R. crenulata met requirements for euthanasia by days 15 and 20, respectively,
compared to the vehicle (14 days). Further, one mouse treated topically with 5% R.
crenulata exhibited complete regression of subcutaneous tumor and survived for over 30
days (Fig. 6B).

Given the differences in growth patterns detected upon topical R. crenulata treatment, we
evaluated the mitotic rate within subcutaneous tumors. We observed that tumors treated
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with vehicle control exhibited significantly more mitotic activity as these tumors had an
average of 2.731 mitotic bodies per high power field while tumors treated with 10% R.
crenulata had an average of 1.714 mitotic bodies per high power field (p=.0374, Fig.
6D).

Knowing that R. crenulata exhibited cytotoxic effects on B16-F10 cells in vitro we
attempted to evaluate these effects in vivo. Fixed, paraffin-embedded tumor sections were
assayed by the TUNEL method to detect DNA nicks that is characteristic of apoptosis.
Subjectively, there appeared to be an increased amount of positive-TUNEL reactions in
R. crenulata treated tumors (Fig. 7); however, these results were confounded by the fact
that both melanin and positive-TUNEL reactions stained brown. Distinguishing positiveTUNEL reactions and melanin pigment in the tumor cells was challenging; thus, we
cannot conclude that there was an increased amount of apoptosis in R. crenulata treated
tumors.

This same problem was encountered when we attempted to evaluate E-cadherin by
immunohistochemistry (IHC). Again, although there appeared to be an increased amount
of E-cadherin in tumors treated with 10% R. crenulata cream, these results were
confounded by the fact that both E-cadherin stain and melanin pigment appears brown
under the microscope (Fig. 7).
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4.2. R. crenulata does not cause tumor regression when administered enterally
Given the differences in growth patterns observed with a topical application of R.
crenulata we decided to test whether these results would be mimicked or amplified in
mice receiving R. crenulata enterally rather than topically. We performed an in vivo
experiment utilizing a subcutaneous syngenic melanoma tumor model in c57bl/6 mice
which we enterally treated with R. crenulata or vehicle through the mice’s water. Tumors
were measured daily using calipers, and for ease of measurement the pigmented region
was what was measured. We did not observe a gross difference in tumor volume between
treatment groups. Additionally, we did not observe a difference in tumor growth patterns.
Mice drinking water supplemented with vehicle reached a tumor volume of 500 mm3 in
12 days, whereas mice drinking water supplemented with R. crenulata reached a tumor
volume of 500 mm3 in 13 days. All mice drinking water supplemented with vehicle met
requirements for euthanasia by day 24 while all mice drinking water supplemented with
R. crenulata met requirements for euthanasia by day 21.

4.3. R. crenulata inhibits establishment of metastatic melanoma
In order to evaluate whether R. crenulata can prevent establishment of metastatic disease,
we provided R. crenulata (100µg/mL) or vehicle control enterally in water to c57bl/6
animals. After three days they were injected via the lateral tail vein with B16-F10 cells
and were monitored following tumor injection for 30 days (Fig. 8A). As previous studies
have suggested that this cell type will metastasize to the lung, we collected the lungs for
analysis. We observed a gross difference in the number of established tumor foci within
the lungs of mice treated with R. crenulata compared to vehicle control (Fig. 8B).
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Further, a significant decrease in lung weight was observed in mice treated with R.
crenulata secondary to a reduced tumor burden (p<0.05, Fig. 8C). Histological analysis
of lungs confirmed reduced establishment of tumor microscopically within the lungs
upon R. crenulata treatment. (Fig. 8B) Pathological consultation suggested that the
reduced tumor burden corresponded with reduced inflammatory involvement and reduced
angiogenesis.
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Figure 6. R. crenulata alters tumor growth and reduces mitotic tumor rate in vivo. (A) Schematic: Topical
Treatment of Subcutaneous Tumor Growth. 1x106 B16-F10 cells were injected subcutaneously in 8-weekold c57bl/6 mice. Injection sites were treated daily with a topical administration of 5%, 10% R. crenulata
or vehicle cream. Every other day, tumor volumes were measured and recorded. Mice were sacrificed when
tumor volume exceeded 1.5cm3 or when 15% of initial body weight was lost. (B) Survival curve for
c57bl/6 mice treated topically with R. crenulata or vehicle cream. An upward trend in survival days for
mice treated topically with 5% or 10% R. crenulata cream was observed. One mouse treated with 5%
cream survived for over 30 days. (C) Image representation of tumors treated topically with 10% R.
crenulata or vehicle cream. Images were captured after the mouse had been sacrificed. (D) Image
representation of histological tumor specimens stained with hematoxylin and eosin. After mice had been
sacrificed, tumors were excised, fixed, paraffin embedded and stained with hematoxylin and eosin. Red
arrows indicate mitotic cells. Images were captured at 40X magnification. (E) The number of mitotic cells
within each representative 40X field was counted. Each sample was photographed three times and the
number of mitotic cells within each represented 40X field was quantified and averaged. Results were
analyzed using a student t-test; bars represent ±SEM. Statistical significance was noted after topical R.
crenulata treatment. (*p<.05).
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Figure 7. Immunohistochemical Analysis of Excised Subcutaneous Tumors. Tumors excised from 10% R.
crenulata and vehicle treated c57bl/6 mice were fixed, and paraffin embedded. Sections were stained with
the indicated reactions/antibodies. Images were captured at 4X, 20X, and 40X magnification.

31

Figure 8. Enteral R. crenulata inhibits establishment of metastatic melanoma in c57bl/6 mice. (A)
Schematic depicting the experimental metastasis model. 72 hours prior to the injection of 10,000 B16-F10
cells via the tail vein, mice were given vehicle control or 100mg/kg R. crenulata supplemented water.
Supplemented water was refreshed every other day. 30 days later, mice were sacrificed and affected tissue
was excised. (B) Image representation of gross excised lungs and histological tumor specimens stained with
hematoxylin and eosin from mice treated enterally with 100mg/kg R. crenulata or vehicle. After 30 days of
treatment, mice were sacrificed and lungs were excised, fixed and photographed. Black residues represent
tumor burden. Lungs were then paraffin embedded and stained with hematoxylin and eosin. (C) Percent of
Total Body Weight. At the time of sacrifice, mice’s body weight was compared to the weight of their lungs.
Results were analyzed using a student t-test; bars represent ±SEM. Statistical significance was noted after
enteral R. crenulata treatment. (*p<.05).
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CHAPTER V
DISCUSSION AND FUTURE DIRECTIONS

Last year melanoma was responsible for the death of 9,710 Americans [1] and the
incidence of this disease continues to rise annually. Melanoma is the most aggressive and
deadliest form of skin cancer and currently, prevention and early detection are the best
methods to reduce these mortality rates as effective treatment options, once diagnosed,
remain limited. Thus, there is a necessity to unearth compounds with therapeutic potential
to combat this deadly disease. Rhodiola plant extracts have exhibited various antitumorigenic properties in a variety of cancers and have been shown to promote cell death
and inhibit both proliferation and angiogenesis [34-35; 40-41]. Given this, R. crenulata
extract and the compounds contained within it, serve as a potential source of novel
melanoma therapy.

In this study, we evaluated the effect of R. crenulata on the aggressive melanoma cell
line, B16-F10. Upon treatment with R. crenulata, B16-F10 cells exhibited morphological
changes, reduced proliferation, increased cell death and reduced colony formation
compared to a vehicle control. While analyzing R. crenulata’s effect on B16-F10 colony
formation, we observed that R. crenulata’s ability to reduce colony establishment was
more effective than that of radiation alone. Combining both R. crenulata and radiation
did not significantly reduce colony establishment when compared to just using R.
crenulata treatment, suggesting that it is not affecting the frequent radio-resistance
exhibited by melanoma cells. Overall, these results reveal the therapeutic potential of R.
crenulata extracts for the treatment of melanoma in vitro.
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Melanoma’s ability to exhibit uninhibited migration contributes to its aggressive
phenotype and high mortality rate. This augmented migratory behavior is due, in part, to
the ID genes. Upregulation of IDS have been associated with tumorigenesis by inhibiting
cell differentiation, stimulating proliferation, enhancing invasiveness and facilitating
tumor growth [42]. Previous studies report that R. crenulata reduces transcriptional levels
of ID-1 and ID-3 in MDA-MB-231 breast cancer cell lines [34]. In this study, we
observed a significant decrease in the transcriptional levels of ID-2 and ID-3 and a
decreasing trend in ID-1 and ID-4 in R. crenulata treated B16-F10 cells. These results
support and further suggest that R. crenulata exerts anti-migratory and anti-proliferative
characteristics on B16-F10 cells.

Another pathway that contributes to melanoma’s ability to migrate and invade is
epithelial-mesenchymal transition (EMT), a reversible switch implicated in the invasive
properties of many carcinomas [43]. Vimentin, a mesenchymal filament protein, is
heavily involved in attachment, migration, and cell signaling [44]. As it is highly
expressed in mesenchymal cells, vimentin serves as an EMT marker and plays a critical
role in wound healing, angiogenesis and cancer growth. Over expression of vimentin
significantly increases the migratory and invasive potential in melanoma cells [15-17]. In
this study, we utilized a scratch wound assay and Matrigel Migration assay to
demonstrate R. crenulata’s ability to inhibit migration. We also showed that R. crenulata
significantly decreased expression levels of vimentin and increased expression of
melanogenesis and E-cadherin in B16-F10 cells. These results suggest that R. crenulata
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may be inducing mesenchymal to epithelial transition (MET) and thus hints at a possible
role in inducing a more differentiated state.

In agreement with a more differentiated state, we observed a flatter growth pattern of
subcutaneous tumors, which is more reminiscent of a transition to radial growth phase
(RGP). This is important because RGP melanomas harbor a 1-2% chance of metastasis
whereas VGP melanomas harbor a metastasis rate of up to 31% [45] within 10 years of
diagnosis. The transition from RGP to VGP, and subsequent increase in metastatic
potential, is frequently associated with the upregulated expression of certain integrins
such as β1 [23; 46; 57]. Importantly, an increase in integrin β1 expression of primary
cutaneous malignant melanomas was observed to be associated with subsequent occult
lymph node metastasis [47]. Upregulated expression of α5, an integrin subunit
predominantly coupled with the integrin β1 subunit, has been associated with B16-F10
metastasis via its interactions with fibronectin [48]. In this study, we observed a decrease
in integrin β1 in response to R. crenulata treatment in vitro consistent with our decreased
migration and decreased adhesion and in support of our in vivo results suggesting a more
differentiated tumor.

Like vertical growth, high mitotic rates in primary cutaneous melanomas are known to be
associated with a more aggressive disease phenotype and lower survival rate [49-52].
Additionally, melanoma tumorigenesis is directly related to a tumor’s mitotic rate [45].
Therapeutic agents that reduce the mitotic rate in melanoma have the potential to reduce
tumor growth and improve outcomes of this disease. In this study, we observed that
tumors treated topically with R. crenulata had significantly less mitotic bodies than
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tumors treated with vehicle control. This further suggests that R. crenulata can reduce the
aggressive potential of melanoma tumors in vivo. Rhodiola plant species have been
previously used topically to reduce melanotic lesions [53], but our study is the first one to
suggest that a topical application may alter and potentially improve melanoma outcomes.
The endpoints for our in vivo subcutaneous study was based on the size of the pigmented
area; however, we had not evaluated the vertical axis in tumor volume measurements.
Thus R. crenulata treated animals may have lasted significantly longer than the vehicle
treated animals if this had been a consideration.

Our second in vivo study evaluated the ability of R. crenulata to prevent metastatic
establishment. Our results revealed that upon enteral administration of R. crenulata in a
disseminated tumor model, the resulting burden of established metastatic foci within the
lung was greatly reduced both grossly and histologically. These results were impressive
and exciting. Following tumor resection, an increase in the amount of circulating
malignant tumor cells in the blood has been observed [54]. This, combined with the
physiological results of stress during the perioperative period following tumor resection
is associated with an increased recurrence rate [55]. Some studies even reveal an
increased in-transit metastases risk in patients with melanoma who remove non-palpable
metastases by elective lymph node dissection following tumour-positive sentinel node
diagnosis [56].We are encouraged that a treatment with the ability to reduce the
establishment of malignant cells following tumor resection would have a significant
preventative and therapeutic impact. Future studies will need to be performed to examine
the effects of R. crenulata on human melanoma lines, as well as to analyze the potential
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of topical treatment to prevent progression from the benign nevi to more malignant
disease.

In conclusion, R. crenulata exhibits promising antineoplastic properties upon treatment of
B16-F10 melanoma, both in vitro and in vivo. As therapeutic options for melanoma
remain limited, identification of novel agents with chemotherapeutic potential, such as R.
crenulata are instrumental in improving survival for those with this aggressive form of
cancer. The future of melanoma therapy may have a place for R. crenulata as an adjuvant
for current treatment methods. In this study, we show that R. crenulata may impede the
transition from RGP to VGP, a key progression involved in the establishment of
metastatic disease. Further, we also demonstrate that a topical administration of R.
crenulata is able to exert protective effects. Finally, we show exciting data for the
potential anti-metastatic activity of this extract.
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